Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics appoints soon-to-be CEO to the board

SkinBio said Stuart John Ashman’s appointment would allow him to gain an understanding of the business while incumbent CEO Dr Cath O’Neill would focus on the company’s scientific developments and ongoing commercial discussions
Board room table
Ashman's board appointment is effective immediately

SkinBioTherapeutics PLC (LON:SBTX) has appointed soon-to-be chief executive, Stuart John Ashman, to the board as an executive director.

Ashman, who was announced as the successor to incumbent CEO Dr Cath O'Neill at the end of March, previously served as the director of sales and marketing at FTSE 100-listed Smith & Nephew PLC (LON:SN.) in its wound care, casting and bandaging division.

READ: SkinBioTherapeutics names ex-Smith & Nephew sales boss as new CEO

SkinBio said Ashman’s appointment to the board would allow him to gain an understanding of the business while O’Neill would focus on the company’s scientific developments and ongoing commercial discussions.

"Stuart's appointment as a director adds further commercial capability to the board. He has a considerable network within the medtech and life science industries and he has the experience and drive to take us forward on the next stage of the company's development," said Martin Hunt, the company’s non-executive chairman.

READ: SkinBioTherapeutics chief "really pleased" with human trial data for new skin cream

O’Neill will likely be turning her attention to the group’s first human study for its SkinBiotix cream, with data last week showing the product had produced a statistically significant increase in skin hydration for the under 50s cohort and a small, but statistically significant decrease in transepidermal water loss at day 29 in the over 60s cohort.

At the time, O’Neill said there was “a lot of scope” for the company to further optimise the formulation of the cream to make it more suitable for different age groups.

In early trading on Thursday, SkinBio shares were down 1.4% at 17.7p.

-- Adds share price --

View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals
word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use